Sex differences in the prevalence and progression of numerous cardiovascular diseases are well documented, with males typically exhibiting greater severity and progression of disease compared with age-matched females. In contrast, females are more likely to develop autoimmune disease compared with age-matched males, both clinically and experimentally. Nevertheless, there is growing evidence that certain autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with an increased risk of developing cardiovascular disease. Based on the expanding literature linking (SLE), are associated with an increased risk of developing cardiovascular disease. Nevertheless, there is growing evidence that certain autoimmune diseases, including systemic lupus erythematosus (SLE), are associated with an increased risk of developing cardiovascular disease. Based on the expanding literature linking male β-estradiol to female sex hormones in cardiovascular disease, data from both animal and clinical research remain controversial. Therefore, it was with great interest that we read the study by Gilbert et al in the current issue of Hypertension, which was designed to determine whether estrogen has a causal role in the development of hypertension in adulthood in SLE, an autoimmune disease with high prevalence of hypertension and cardiovascular disease. Using an established mouse model of SLE (female NZBWF1), Gilbert et al have directly confirmed a protective role for 17β-estradiol against SLE-mediated hypertension and proteinuria in adult female mice, in part, by reducing tumor necrosis factor-α. In this study, animals were ovarioctomized at 30 weeks and studied at 34 weeks, and the results are in contrast to those obtained where estrogens potentiate the onset of SLE when mice are ovarioctomized at <6 to 8 weeks. Together, these studies suggest that female sex hormones may act as a double-edged sword in the development and progression of hypertension in SLE, with timing being the critical determinant of the inflammatory and cardiovascular impact of estrogen. The authors suggest that there are temporal effects of estrogen in SLE, with estrogens promoting humoral immunity during subclinical disease but protecting against inflammation and disease progression in adulthood.

It is well established that 17β-estradiol binds to its cognate receptors (ie, estrogen receptor α and estrogen receptor β) to initiate extranuclear cytosolic signaling pathways and nuclear expression of specific genes by associating with transcriptional cofactors. Nongenomic mechanisms trigger downstream signaling events through rapid post-translational modifications of numerous membrane and cytosolic signaling molecules, including mitogen-activated protein kinase, phosphatidylinositide 3-kinase, Akt, and endothelial nitric oxide (NO) synthase, which are critical in initiating an immediate response. One result of this concerted signaling cascade is an elevation of NO bioavailability, and NO has been suggested to be a primary mechanism for the protection of females against cardiovascular diseases and may contribute to the better resistance against infection among females.

However, during conditions of oxidative stress even an increase in NO could do a disservice through the formation of deleterious peroxynitrite and protein nitration, which contributes to additional cellular damage. There is evidence supporting an NO deficiency in SLE; therefore, any additional decrease in NO may potentiate disease progression in SLE, as well as many other cardiovascular diseases. Importantly, these detrimental effects will be primarily evident in acute pathological events, when the antioxidant properties of estrogens have a limited time to affect antioxidant potential compared with the robust increase in free radical production. SLE is known to be associated with increases in oxidative stress, apoptosis, and cellular injury. Indeed, the formation of autoantibodies against epitopes from apoptotic cells is known to be among the earliest symptoms and a hallmark of SLE. Moreover, elevated levels of anti-nitrotyrosine antibodies in serum of patients with SLE have been suggested to be responsible for the breakdown or bypass of self-tolerance. Therefore, under certain conditions, estrogen could actually promote increases in oxidative damage and disease progression. Alternatively, because decreases in NO bioavailability promote inflammation, and early loss of estrogen in SLE may promote disease progression, it could be speculated that the early loss of NO promotes SLE-induced cardiovascular disease.

In contrast, chronic low-level inflammation in established SLE may provide an adequate amount of time to reveal the protective properties of estrogen, as evidenced in the study by Gilbert et al, where mice were allowed to mature fully and were well into adulthood before sex hormones were removed.
NO not only acts as a potent vasodilator, but also possesses antithrombotic, anti-inflammatory, and antiproliferative properties. Estrogen also elicits genomic mechanisms mediating relatively slow changes in gene expression, including antioxidant proteins. Therefore, long-term exposure to estrogens has the potential to induce multiple lines of defense against the development of cardiovascular disease. Our group recently reported that treatment with the nonselective NO synthase inhibitor NG-nitro-L-arginine methyl ester resulted in greater increases in blood pressure in female spontaneously hypertensive rats than males. Moreover, this increase was associated with greater increases in renal adhesion molecule expression and Th17 cell infiltration, which have been linked to the development of autoimmune disease. Our data suggest that NO is a critical regulator of blood pressure and the immune cell profile, particularly in females. Hence, an increase in NO bioavailability induced by estrogen, while damaging during acute oxidative stress, could postpone the development of cardiovascular complications, as demonstrated by Gilbert et al. In conclusion, the present study provides a new paradigm for a dual role of estrogen in the initiation and progression of SLE, as well as offering protection against the progression of disease. Future investigations that directly confirm the particular molecular mechanisms behind female sex hormone dualism will allow for more defined control of estrogenic activity to achieve beneficial effects regardless of the stage of immune disease.

Sources of Funding
Dr Sullivan is funded by the National Institutes of Health grant 1R01 HL-093271-01A1.

Disclosures
None.

References
Estrogen: Good, Bad, or Both?
Olga Rafikova and Jennifer C. Sullivan

*Hypertension*. 2014;63:449-450; originally published online December 23, 2013; doi: 10.1161/HYPERTENSIONAHA.113.02500

*Hypertension* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0194-911X. Online ISSN: 1524-4563

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://hyper.ahajournals.org/content/63/3/449

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Hypertension* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to *Hypertension* is online at:
http://hyper.ahajournals.org//subscriptions/